請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/18525完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 謝淑貞(Shu-Chen Hsieh) | |
| dc.contributor.author | Ting-Yu Chao | en |
| dc.contributor.author | 趙庭郁 | zh_TW |
| dc.date.accessioned | 2021-06-08T01:09:49Z | - |
| dc.date.copyright | 2014-09-03 | |
| dc.date.issued | 2014 | |
| dc.date.submitted | 2014-08-18 | |
| dc.identifier.citation | Akhter, M. P., Iwaniec, U. T., Covey, M. A., Cullen, D. M., Kimmel, D. B., & Recker, R. R. (2000). Genetic variations in bone density, histomorphometry, and strength in mice. Calcified Tissue International, 67, 337–344. doi:10.1007/s002230001144
Arts, J., Kuiper, G. G. J. M., Janssen, J. M. M. F., Gustafsson, J.-A., Lowik, C. W. G. M., Pols, H. A. P., & Van Leeuwen, J. P. T. M. (1997). Differential expression of estrogen receptors alpha and beta mRNA during differentiation of human osteoblast SV-HFO cells. Endocrinology, 138(11), 5067–5070. Atteritano, M., Mazzaferro, S., Frisina, A., Cannata, M. L., Bitto, A., D’Anna, R., … Buemi, M. (2009). Genistein effects on quantitative ultrasound parameters and bone mineral density in osteopenic postmenopausal women. Osteoporosis International, 20(11), 1947–54. doi:10.1007/s00198-009-0883-4 Beamer, W. G., Donahue, L. R., Rosen, C. J., & Baylink, D. J. (1996). Genetic variability in adult bone density among inbred strains of mice. Bone, 18(5), 397–403. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8739896 Bitto, A., Burnett, B. P., Polito, F., Marini, H., Levy, R. M., Armbruster, M. A., … Altavilla, D. (2008). Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol. British Journal of Pharmacology, 155(6), 896–905. doi:10.1038/bjp.2008.305 Bitto, A., Granese, R., Triolo, O., Villari, D., Maisano, D., Giordano, D., … Squadrito, F. (2010). Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia. Phytomedicine : International Journal of Phytotherapy and Phytopharmacology, 17(11), 844–50. doi:10.1016/j.phymed.2010.03.024 Bord, S., Horner, a, Beavan, S., & Compston, J. (2001). Estrogen receptors alpha and beta are differentially expressed in developing human bone. The Journal of Clinical Endocrinology and Metabolism, 86(5), 2309–14. doi:10.1210/jcem.86.5.7513 Cauley, J. A., Robbins, J., Chen, Z., Cummings, S. R., Jackson, R. D., Lacroix, A. Z., … Wactawski-wende, J. (2014). Effects of estrogen plus progestin on risk of fracture and bone mineral density. Journal of the American Medical Association, 290(13), 1729–1738. Cauley, J. A., Zmuda, J. M., Ensrud, K. E., Bauer, D. C., & Ettinger, B. (2001). Timing of estrogen replacement therapy for optimal osteoporosis prevention. The Journal of Clinical Endocrinology and Metabolism, 86(12), 5700–5. doi:10.1210/jcem.86.12.8079 Chesnut, C. H., Azria, M., Silverman, S., Engelhardt, M., Olson, M., & Mindeholm, L. (2008). Salmon calcitonin: a review of current and future therapeutic indications. Osteoporosis International, 19(4), 479–91. doi:10.1007/s00198-007-0490-1 Chesnut, C. H., Silverman, S., Andriano, K., Genant, H., Gimona, A., Harris, S., … Study, P. (2000). A Randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. American Journal of Medicine, 109(4), 267–276. Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. (1993). American Journal of Medicine, 94(6), 646–650. doi:10.1016/0002-9343(93)90218-E Cummings, S. R., San Martin, J., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., … Christiansen, C. (2009). Denosumab for prevention of fractures in postmenopausal women with osteoporosis. The New England Journal of Medicine, 361(8), 756–65. doi:10.1056/NEJMoa0809493 Delmas, P. D., Bjarnason, N. H., Mitlak, B. H., Ravoux, A.-C., Shah, A. S., Huster, W. J., … Christiansen, C. (1997). Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. The New England Journal of Medicine, 337(23), 1641–1647. Dixon, R. A., & Ferreira, D. (2002). Genistein. Phytochemistry, 60(3), 205–11. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12031439 Ettinger, B., Black, D. M., Mitlak, B. H., Knickerbocker, R. K., Nickelsen, T., Genant, H. K., … Avioli, L. V. (1999). Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized trial, 282(7). Fanti, P., Geng, Z., Schmidt, J., Morris, P. E., Cohen, D., & Malluche, H. H. (1998). The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats. Osteoporosis International, 8, 274–281. Galie, T. L., Lynch, M. E., Main, R. P., & van der Meulen, M. C. H. (2010). The ovariectomized mouse as a model for osteoporosis. Proceedings of the 2010 IEEE 36th Annual Northeast Bioengineering Conference (NEBEC), 1–2. doi:10.1109/NEBC.2010.5458136 Gal-Moscovici, A., & Sprague, S. M. (2007). Osteoporosis and chronic kidney disease. Seminars in Dialysis, 20(5), 423–30. doi:10.1111/j.1525-139X.2007.00319.x Gennari, C. (2002). Analgesic effect of calcitonin in osteoporosis. Bone, 30(5 Suppl), 67S–70S. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12008161 Greenspan, S. L., Bone, H. G., Ettinger, M. P., Hanley, D. A., Lindsay, R., Zanchetta, J. R., … Marriott, T. B. (2007). Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Annals of Internal Medicine, 146(5), 326–339. Retrieved from http://dx.doi.org/10.7326/0003-4819-146-5-200703060-00005 Greenspan, S. L., Rosen, H. N., & Parker, R. A. (2000). Early changes in serum N-telopeptide and C-telopeptide predict cross-linked collagen type I predict long-term response to alendronate therapy in ederly women, 85(10), 3537–3540. Halleen, J. M., Alatalo, S. L., Suominen, H., Cheng, S., Janckila, A. J., & Vaananen, H. K. (2000). Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. Journal of Bone and Mineral Research, 15(7), 1337–45. doi:10.1359/jbmr.2000.15.7.1337 Hsieh, C., Santell, R. C., Haslam, S. Z., & Helferich, W. G. (1998). Estrogenic effects of genistein on the growth of estrogen receptor-positive human beast cancer (MCF-7) cells in vitro and in vivo. Cancer Research, 58, 3833–3838. Hsu, C., Ho, H.-W., Chang, C.-F., Wang, S.-T., Fang, T.-F., Lee, M.-H., & Su, N.-W. (2013). Soy isoflavone-phosphate conjugates derived by cultivating Bacillus subtilis var. natto BCRC 80517 with isoflavone. Food Research International, 53(1), 487–495. doi:10.1016/j.foodres.2013.05.027 Hwang, J. S., Chen, J. F., Yang, T. S., Wu, D. J., Tsai, K. S., Ho, C., … Tu, S. T. (2008). The effects of strontium ranelate in Asian women with postmenopausal osteoporosis. Calcified Tissue International, 83(5), 308–14. doi:10.1007/s00223-008-9180-z Hwang, J. S., Tu, S. T., Yang, T. S., Chen, J. F., Wang, C. J., & Tsai, K. S. (2006). Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporosis International. doi:10.1007/s00198-005-2002-5 Idris, A. I. (2012). Ovariectomy/Orchidectomy in Rodents. In M. H. Helfrich & S. H. Ralston (Eds.), Bone Research Protocols, Methods in Molecular Biology (Vol. 816, pp. 545–551). Totowa, NJ: Humana Press. doi:10.1007/978-1-61779-415-5 Iwaniec, U. T., Yuan, D., Power, R. A., & Wronski, T. J. (2006). Strain-dependent variations in the response of cancellous bone to ovariectomy in mice. Journal of Bone and Mineral Research, 21(7), 1068–1074. doi:10.1359/JBMR.060402 Jee, W. S., & Yao, W. (2001). Overview: animal models of osteopenia and osteoporosis. Journal of Musculoskeletal & Neuronal Interactions, 1(3), 193–207. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15758493 Jochems, C., Islander, U., Erlandsson, M., Verdrengh, M., Ohlsson, C., & Carlsten, H. (2005). Osteoporosis in experimental postmenopausal polyarthritis: The relative contributions of estrogen deficiency and inflammation. Arthritis Research & Therapy, 7(4), R837–43. doi:10.1186/ar1753 Kaemmerer, D., Schmidt, B., Lehmann, G., Wolf, G., Settmacher, U., & Hommann, M. (2012). Treatment of bone loss in patients with chronic liver disease awaiting liver transplantation. Transplantation Research, 1(1), 7. doi:10.1186/2047-1440-1-7 Kanis, J. A. (2002). Diagnosis of osteoporosis and assessment of fracture risk. Lancet, 359(9321), 1929–36. doi:10.1016/S0140-6736(02)08761-5 Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994). The diagnosis of osteoporosis. Journal of Bone and Mineral Research, 9(8), 1137–1141. doi:10.1002/jbmr.5650090802 Kwon, S. H., Kang, M. J., Huh, J. S., Ha, K. W., Lee, J. R., Lee, S. K., … Choi, Y. W. (2007). Comparison of oral bioavailability of genistein and genistin in rats. International Journal of Pharmaceutics, 337(1-2), 148–54. doi:10.1016/j.ijpharm.2006.12.046 Lee, J., & Vasikaran, S. (2012). Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis. Annals of Laboratory Medicine, 32(2), 105–12. doi:10.3343/alm.2012.32.2.105 Lindsay, R., Gallagher, J. C., Kleerekoper, M., & Pickar, J. H. (2014). Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAMA : The Journal of the American Medical Association, 287(20), 2668–76. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12020302 Liu, Y., & Hu, M. (2002). Absorption and metabolism of flavonoids in the Caco-2 cell culture model and a perused rat intestinal model. Drug Metabolism and Disposition, 30(4), 370–377. MacLennan, A., Broadbent, J., Lester, S., & Moore, V. (2009). Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes (Review). Cochrane Database System Review, 18. Marini, H., Bitto, A., Altavilla, D., Burnett, B. P., Polito, F., Di Stefano, V., … Squadrito, F. (2008). Breast safety and efficacy of genistein aglycone for postmenopausal bone loss: a follow-up study. The Journal of Clinical Endocrinology and Metabolism, 93(12), 4787–96. doi:10.1210/jc.2008-1087 Marini, H., Minutoli, L., Polito, F., Bitto, A., Altavilla, D., Atteritano, M., … Squadrito, F. (2007). Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women. Annals of Internal Medicine, 146(12), 839–847. Martin. (2012). Morphometric indices: Trabecular thickness (Tb. Th), trabecular spacing (Tb. Sp), trabecular number (Tb. N). Mason, A. C., Evers, W. D., & Hanley, E. E. (2001). Osteoporosis: What you should know. National Osteoporosis Foundation. Retrieved from https://www.purdue.edu/enjoyfoodbeactive/factsheets/nutrition/osteoporosiswhatyoushouldknow.aspx McClung, M. R., Leweichi, E. M., Cohen, S. B., Bolognese, M. A., Woodson, G. C., Moffett, A. H., … Bekker, P. J. (2006). Denosumab in postmenopausal women with low bone mineral density. The New England Journal of Medicine, 354, 821–831. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/24676847 Mehta, N. M., Malootian, A., & Gilligan, J. P. (2003). Calcitonin for Osteoporosis and Bone Pain. Current Pharmaceutical Design, 9(32), 2659–2676. Retrieved from http://www.ingentaconnect.com/content/ben/cpd/2003/00000009/00000032/art00003 Messina, M. (2014). Soy foods, isoflavones, and the health of postmenopausal women. The American Journal of Clinical Nutrition, 100, 423S–430S. doi:10.3945/ajcn.113.071464.2 Meunier, P. J., Roux, C., Seeman, E., Ortolani, S., Badurski, J. E., Spector, T. D., … Reginster, J.-Y. (2004). The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. The New England Journal of Medicine, 350(5), 459–68. doi:10.1056/NEJMoa022436 Ming, L.-G., Chen, K.-M., & Xian, C. J. (2013). Functions and action mechanisms of flavonoids genistein and icariin in regulating bone remodeling. Journal of Cellular Physiology, 228(3), 513–21. doi:10.1002/jcp.24158 Miyauchi, Y., Sato, Y., Kobayashi, T., Yoshida, S., Mori, T., & Kanagawa, H. (2013). HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. PNAS, 110(41), 16568–16573. doi:10.1073/pnas.1308755110/-/DCSupplemental.www.pnas.org/cgi/doi/10.1073/pnas.1308755110 Morabito, N., Crisafulli, A., Vergara, C., Gaudio, A., Lasco, A., Frisina, N., … Squadrito, F. (2002). Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study. Journal of Bone and Mineral Research, 17(10), 1904–12. doi:10.1359/jbmr.2002.17.10.1904 Morito, K., Hirose, T., Kinjo, J., Hirakawa, T., Okawa, M., Nohara, T., … Masamune, Y. (2001). Interaction of phytoestrogens with estrogen receptors alpha and beta. Biological and Pharmaceutical Bulletin, 24(4), 351–356. National Osteoporosis Foundation. (2004). Strong Voices for Strong Bones (Vol. 145, pp. 4692–4692). doi:10.1210/endo.145.10.9995 Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J. Y., … Mitlak, B. H. (2001). Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. The New England Journal of Medicine, 344(19), 1434–41. doi:10.1056/NEJM200105103441904 Onoe, Y., Miyaura, C., Hota, H., Nozawa, S., & Suda, T. (1997). Expression of estrogen receptor beta in rat bone. Endocrinology, 138(10), 4509–4512. Park, J. A., Ha, S. K., Kang, T. H., Oh, M. S., Cho, M. H., Lee, S. Y., … Kim, S. Y. (2008). Protective effect of apigenin on ovariectomy-induced bone loss in rats. Life Sciences, 82(25-26), 1217–23. doi:10.1016/j.lfs.2008.03.021 Park-Wyllie, L. Y., Mamdani, M. M., Juurlink, D. N., Hawker, G. A., Gunraj, N., Austin, P. C., … Laupacis, A. (2011). Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. Journal of the American Medical Association, 305(8), 783–9. doi:10.1001/jama.2011.190 Prentice, A. (2007). Diet, nutrition and the prevention of osteoporosis. Public Health Nutrition, 7(1a), 227–243. doi:10.1079/PHN2003590 Recommendations for preventing osteoporosis. (2002). In Diet, nutrition and the prevention of chronic diseases Report of the joint WHO/FAO expert consultation (pp. 129–133). WHO Technical Report Series, No. 916 (TRS 916). Retrieved from http://www.who.int/dietphysicalactivity/publications/trs916/en/gsfao_osteo.pdf?ua=1 Reinwald, S., & Weaver, C. M. (2006). Soy isoflavones and bone health: a double-edged sword? Journal of Natural Products, 69(3), 450–9. doi:10.1021/np058104g Rendina, E., Hembree, K. D., Davis, M. R., Marlow, D., Clarke, S. L., Halloran, B. P., … Smith, B. J. (2013). Dried plum’s unique capacity to reverse bone loss and alter bone metabolism in postmenopausal osteoporosis model. PloS One, 8(3), e60569. doi:10.1371/journal.pone.0060569 Rissanen, J. P., Suominen, M. I., Peng, Z., & Halleen, J. M. (2008). Secreted tartrate-resistant acid phosphatase 5b is a Marker of osteoclast number in human osteoclast cultures and the rat ovariectomy model. Calcified Tissue International, 82(2), 108–15. doi:10.1007/s00223-007-9091-4 Rissanen, J. P., Suominen, M. I., Peng, Z., Morko, J., Rasi, S., Risteli, J., & Halleen, J. M. (2008). Short-term changes in serum PINP predict long-term changes in trabecular bone in the rat ovariectomy model. Calcified Tissue International, 82(2), 155–61. doi:10.1007/s00223-007-9101-6 Rouillard, S., & Lane, N. E. (2001). Hepatic osteodystrophy. Hepatology (Baltimore, Md.), 33(1), 301–7. doi:10.1053/jhep.2001.20533 Santell, R. C., Chang, Y. C., Nair, M. G., & Helferich, W. G. (1997). Dietary genistein exerts estrogenic effects upon the uterus, mammary gland and the hypothalamic/pituitary axis in aats. Journal of Nutrition, (June 1996), 263–269. Seibel, M. J. (2006). Biochemical markers of bone turnover. Part II: Clinical applications in the management of osteoporosis. The Clinical Biochemist Reviews, 27(3), 123–38. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1579289&tool=pmcentrez&rendertype=abstract Setchell, K. D. R., & Lydeking-Olsen, E. (2003). Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. The American Journal of Clinical Nutrition, 78(3 Suppl), 593S–609S. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12936954 Shackelford, C., Long, G., Wolf, J., Okerberg, C., & Herbert, R. (2002). Qualitative and quantitative analysis of nonneoplastic lesions in toxicology studies. Toxicologic Pathology, 30(1), 93–96. doi:10.1080/01926230252824761 Steensma, A., Noteborn, H. P., Jagt, R. C., Polman, T. H., Mengelers, M. J., & Kuiper, H. A. (1999). Bioavailability of genistein, daidzein, and their glycosides in intestinal epithelial Caco-2 cells. Environmental Toxicology and Pharmacology, 7(3), 209–12. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/21781927 Structural parameters measured by the Skyscan TM CT-analyser software. (1987). Aartselaar, Belgium. Tai, T. Y., Tsai, K. S., Tu, S. T., Wu, J. S., Chang, C. I., Chen, C. L., … Wu, C. H. (2012). The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: a 2-year randomized double-blind placebo-controlled study. Osteoporosis International, 23(5), 1571–80. doi:10.1007/s00198-011-1750-7 Taku, K., Melby, M. K., Kurzer, M. S., Mizuno, S., Watanabe, S., & Ishimi, Y. (2010). Effects of soy isoflavone supplements on bone turnover markers in menopausal women: systematic review and meta-analysis of randomized controlled trials. Bone, 47(2), 413–23. doi:10.1016/j.bone.2010.05.001 Teitelbaum, S. L. (2000). Bone resorption by osteoclasts. Science, 289(5484), 1504–1508. doi:10.1126/science.289.5484.1504 Tsai, K.-S., Yang, R.-S., Wu, C.-H., Hwang, J.-S., Cheng, T.-T., & Sun, Z.-J. (2012a). Taiwan osteoporosis practice guidelines (pp. 1–120). Bureau of Health Promotion, Department of Health, ROC (Taiwan), National Health Research Institutes, The Taiwanese Osteoporosis Association. Tsai, K.-S., Yang, R.-S., Wu, C.-H., Hwang, J.-S., Cheng, T.-T., & Sun, Z.-J. (2012b). Taiwanese guidelines for the prevention and rreatment of osteoporosis. Taiwanese Osteoporosis Association, 1–25. Turner, A. S. (2001). Animal models of osteoporosis--necessity and limitations. European Cells & Materials, 1, 66–81. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/14562261 Turner, R. T., Iwaniec, U. T., Andrade, J. E., Branscum, A. J., Neese, S. L., Olson, D. A., … Helferich, W. G. (2013). Genistein delivered as a once daily oral supplement had no beneficial effect on the rat tibia in rat models of postmenopausal bone loss. National Institutes of Health, 20(6), 677–686. doi:10.1097/gme.0b013e31827d44df.Genistein Turner, R. T., Maran, A., Lotinun, S., Hefferan, T., Evans, G. L., Zhang, M., & Sibonga, J. D. (2001). Animal models for osteoporosis. Reviews in Endocrine & Metabolic Disorders, 2, 117–127. Vasikaran, S., Eastell, R., Bruyere, O., Foldes, A. J., Garnero, P., Griesmacher, A., … Kanis, J. A. (2011). Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment : a need for international reference standards. Osteoporosis International, 22, 391–420. doi:10.1007/s00198-010-1501-1 Vasikaran, S., Glendenning, P., & Morris, H. A. (2006). The role of biochemical markers of bone turnover in osteoporosis management in clinical practice. The Clinical Biochemist. Reviews / Australian Association of Clinical Biochemists, 27(3), 119–21. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1579290&tool=pmcentrez&rendertype=abstract Wang, J., Shang, F., Liu, L., Wang, J., & Mei, Q. (2007). In vivo and in vitro activity of genistein in osteoporosis. Indian Journal of Pharmacology, 39(2), 103–106. Wang, T. T. Y., Sathyamoorthy, N., & Phang, J. M. (1996). Molecular effects of genistein on estrogen receptor mediated pathways. Carcinogenesis, 17(2), 271–5. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8625449 Wangen, K. E., Duncan, a M., Merz-Demlow, B. E., Xu, X., Marcus, R., Phipps, W. R., & Kurzer, M. S. (2000). Effects of soy isoflavones on markers of bone turnover in premenopausal and postmenopausal women. The Journal of Clinical Endocrinology and Metabolism, 85(9), 3043–8. doi:10.1210/jcem.85.9.6787 Wei, P., Liu, M., Chen, Y., & Chen, D.-C. (2012). Systematic review of soy isoflavone supplements on osteoporosis in women. Asian Pacific Journal of Tropical Medicine, 5(3), 243–8. doi:10.1016/S1995-7645(12)60033-9 World Health Organization. (1998). Guidelines for preclinical evaluation and clinical trials in osteoporosis World Health Organization. Geneva: World Health Organization. Wright, L. E., Christian, P. J., Rivera, Z., Alstine, W. G. Van, Funk, J. L., Bouxsein, M. L., & Hoyer, P. B. (2008). Comparison of skeletal effects of ovariectomy versus chemically induced ovarian failure in mice. Journal of Bone and Mineral Research, 23(8), 1296–1303. doi:10.1359/JBMR.080309 Wu, A. H., Stanczyk, F. Z., Hendrich, S., Murphy, P. A., Zhang, C., Wan, P., & Pike, M. C. (2000). Effects of soy foods on ovarian function in premenopausal women. British Journal of Cancer, 82(11), 1879–86. doi:10.1054/bjoc.1999.1218 Yang, X.-Z., Ji, C.-J., Wang, D.-C., & Chen, X.-L. (2012). Antiosteoporotic activity of lycopene in mature ovariectomized rats. Chinese Journal of Tissue Engineering Research, 16(15), 2750–2756. Yates, J., Barrett-Connor, E., Barlas, S., Chen, Y. T., Miller, P. D., & Siris, E. S. (2004). Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk ASsessment. Obstetrics & Gynecology, 103(3), 440–446. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/18525 | - |
| dc.description.abstract | 國內外很高比例的停經後婦女都患有骨質疏鬆症，帶來很多危害健康的風險，例如骨折的產生。其主要病因為雌激素缺乏。臨床上常用的賀爾蒙治療法即是給予雌激素，可減少骨折風險但是卻會引起不良副作用，例如增加罹患乳癌與心血管疾病的風險。大豆異黃酮(genistein)是一種植物性雌激素，因其結構與人體雌激素類似，可與體內雌激素受體結合並有類雌激素的效果。已有研究顯示genistein可用於減緩部分女性更年期症狀，且對於骨質疏鬆的延緩甚至預防較賀爾蒙給予有效用佳卻幾乎沒有副作用的優勢。但是身為親油性的物質，它的水溶性並不好。為了提升生物利用率，我們藉由化學修飾改變其結構與增加其水溶性，也在體外試驗看到更佳的吸收率。因此本研究利用停經後骨質疏鬆的小鼠模式探討genistein與modified genistein (genistein 7-O-phosphate)兩者保護骨頭的作用。研究結果顯示modified genistein比genistein更能維持骨頭微結構的完整，因此推測modified genistein具有更佳的抗骨鬆效用。 | zh_TW |
| dc.description.abstract | Increase in bone turnover associated with ovarian hormone deficiency after menopause facilitates the development of postmenopausal osteoporosis. Conventional treatment for postmenopausal osteoporosis is hormone replacement therapy (HRT) which is a prescription of exogenous estrogen. However, several undesirable side effects are associated with HRT, including elevated risk of breast cancer and cardiovascular events. On the other hand, genistein is an estrogenic isoflavone found mainly in soybeans and soy products; long-term clinical studies indicate that genistein appears to be one of the most effective and safe isoflavone in preserving bone health. Nevertheless, its poor aqueous solubility contributes to low bioavailability. An isoflavone derivative, genistein 7-O-phosphate, has been obtained by microbial bioconversion and found to be more rapidly absorbed into the intestine than the parent drug in Caco-2 absorption study. Evaluation of micro-computed tomography analysis of bone microarchitecture shows that treatment with genistein 7-O-phosphate results in more complete preservation of bone tissue integrity than genistein. Given this finding, the modified genistein seems to have greater potential in preserving bone health than genistein. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-08T01:09:49Z (GMT). No. of bitstreams: 1 ntu-103-R01641039-1.pdf: 3106089 bytes, checksum: 4766279d8dbf0cec0113a8e13b5dcb61 (MD5) Previous issue date: 2014 | en |
| dc.description.tableofcontents | Table of Contents
口試委員會審定書 ii Acknowledgement iii 中文摘要 iv Abstract v Chapter 1. Introduction 1 1.1 Overview 1 1.2 Literature Review 2 1.2.1 Bone Biology 2 1.2.2 Osteoporosis 3 Definition and Pathophysiology 3 Diagnosis 5 Risk Factors 7 Prevention and Treatment 8 1.2.3 Estrogen and Postmenopausal Osteoporosis 15 1.2.4 Genistein 16 Structure and Estrogenic Activity 16 Effects on Bone 20 Absorption Study 22 1.2.5 Genistein 7-O-Phosphate 23 1.2.6 Rodent Models of Osteoporosis 24 Chapter 2. Aims 27 2.1 Research Motivation 27 2.2 Hypothesis 28 2.3 Experimental Framework 29 Chapter 3. Materials and Methods 30 3.1 Materials 30 3.1.1 Study Samples 30 3.1.2 Chemicals 30 3.1.3 Instruments 31 3.1.4 Kits 32 3.2 Methods 32 3.2.1 Animals 32 3.2.2 Measurement of Blood Concentration of Genistein 34 3.2.3 Measurement of Bone Densitometry and Bone Microarchitecture 35 3.2.4 Histopathology of Bone Tissue 36 3.2.5 Measurement of Serum Bone Turnover Markers 37 3.2.6 Statistical Analysis 37 Chapter 4. Results 38 4.1 Anthropometric Analysis 38 4.2 Plasma Concentration of Genistein 44 4.3 Bone Mineral Density and Bone Microarchitecture 45 4.4 Histopathology of Bone Tissue 51 4.5 Serum Bone Turnover Markers 58 4.5.1 Bone Formation Marker 58 4.5.2 Bone Resorption Markers 59 Chapter 5. Discussion 61 Chapter 6. Conclusion 68 Chapter 7. Appendix 70 Chapter 8. References 71 | |
| dc.language.iso | en | |
| dc.title | 化學修飾之大豆異黃酮延緩卵巢摘除小鼠之骨質疏鬆的功效 | zh_TW |
| dc.title | Anti-osteoporotic Effects of Modified Genistein in Ovariectomized Mice | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 102-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 蘇南維(Nan-Wei Su),潘敏雄(Ming-Hsiung Pan) | |
| dc.subject.keyword | 大豆異黃酮 (genistein、genistein 7-O-phosphate),雌激素缺乏,骨質疏鬆症, | zh_TW |
| dc.subject.keyword | postmenopausal osteoporosis,estrogen deficiency,genistein 7-O-phosphate,genistein, | en |
| dc.relation.page | 88 | |
| dc.rights.note | 未授權 | |
| dc.date.accepted | 2014-08-18 | |
| dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
| dc.contributor.author-dept | 食品科技研究所 | zh_TW |
| 顯示於系所單位： | 食品科技研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-103-1.pdf 目前未授權公開取用 | 3.03 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。